Citations

Clear

421 citation(s) found for "Short, C".

Altered regulation of energy homeostasis in older rats in response to thyroid hormone administration
Walrand, Stéphane , Short, Kevin R. , Heemstra, Lydia A., Novak, Colleen M. , Levine, James A. , Coenen-Schimke, Jill M., Nair, K. Sreekumaran

Mayo Clinic

The FASEB Journal | December 16, 2013 | Volume: 28 | Issue: 3 | Pages: 1499-1510

10.1096/fj.13-239806 | PMID 24344330 Get It

Hyperthyroidism causes increased energy intake and expenditure, although anorexia and higher weight loss have been reported in elderly individuals with hyperthyroidism. To determine the effect of age on energy homeostasis in response to experimental hyperthyroidism, we administered 200 μg triiodothyronine (T3) in 7‐ and 27‐mo‐old rats for 14 d. T3 increased energy expenditure (EE) in both the young and the old rats, although the old rats lost more weight (147 g) than the young rats (58 g) because of the discordant effect of T3 on food intake, with a 40% increase in the young rats, but a 40% decrease in the old ones. The increased food intake in the young rats corresponded with a T3‐mediated increase in the appetite‐regulating proteins agouti‐related peptide, neuropeptide Y, and uncoupling protein 2 in the hypothalamus, but no increase occurred in the old rats. Evidence of mitochondrial biogenesis in response to T3 was similar in the soleus muscle and heart of the young and old animals, but less consistent in old plantaris muscle and liver. Despite the comparable increase in EE, T3's effect on mitochondrial function was modulated by age in a tissue‐specific manner. We conclude that older rats lack compensatory mechanisms to increase caloric intake in response to a T3‐induced increase in EE, demonstrating a detrimental effect of age on energy homeostasis.—Walrand, S., Short, K. R., Heemstra, L. A., Novak, C. M., Levine, J. A., Coenen‐Schimke, J. M., Nair, K. S. Altered regulation of energy homeostasis in older rats in response to thyroid hormone administration. FASEB J. 28, 1499–1510 (2014). www.fasebj.org
Comparison of Glucose Counterregulation During Short-Term and Prolonged Hypoglycemia in Normal Humans
Feo, Pierpaolo De , Perriello, G. , Cosmo, Salvatorec De, Ventura, M. M., Campbell, Peter J. , Brunetti, Paolo, Gerich, John E., Bolli, Geremia B.

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 35 | Issue: 5 | Pages: 563-569

10.2337/diab.35.5.563 Get It

To compare glucose counter regulatory mechanisms during short-term hypoglycemia and prolonged hypoglycemia, insulin was infused either intravenously (160 mil · M−2 · min) for 10 min or subcutaneously (15 mU · M−2 · min) for 12 h in normal volunteers. With each type of insulin infusion, hypoglycemia (∼50 mg/dl) was either allowed to develop or was prevented (control experiments) by the glucose-clamp technique. During prolonged hypoglycemia, both increased glucose production (1.55 ± 0.05 versus 0.33 ± 0.14 mg · kg−1 · min in control experiments at 12 h, P < 0.01) and suppressed glucose utilization (1.55 ± 0.06 versus 3.17 ± 0.15 mg · kg−1 · min in control studies at 12 h, P < 0.01) were involved in counterregulation. During short-term hypoglycemia, only increased glucose production (3.23 ± 0.33 versus 0.06 ± 0.03 mg · kg−1 · min in control experiments at 60 min) was involved, since glucose clearance actually increased (3.99 ± 0.20 versus 2.88 ± 0.02 ml · kg−1 · min in control experiments at 60 min, P < 0.01). Estimated portal venous insulin concentrations decreased 40% (basal 24 ± 3 versus 14 ± 1 mU/ml at 60 min, P < 0.01) in the short-term hypoglycemia experiments but remained at basal levels (basal 25 ± 1 versus ∼26 μU/min between 1 and 12 h) during prolonged hypoglycemia. Despite the fact that hypoglycemia was more gradually induced in the prolonged hypoglycemia model, peak counterregulatory hormone responses were at least as great as those during short-term hypoglycemia. Plasma free fatty acids and ketone bodies increased 150–200% above basal (both P < 0.01) with counterregulation during prolonged hypoglycemia but did not increase above basal levels with counterregulation during short-term hypoglycemia. Finally, plasma alanine remained unchanged during short-term hypoglycemia but decreased nearly 40% during prolonged hypoglycemia (basal 327 ± 20 versus 208 ± 21 μM at 12 h, P < 0.01). We conclude that glucose counterregulatory mechanisms differ during short-term and prolonged hypoglycemia. In the former, only an increase in glucose production mediated by suppression of insulin secretion and increased glucagon secretion is involved, whereas during prolonged hypoglycemia, both a suppression of glucose utilization, and an increase in glucose production are important. These latter changes in glucose production and utilization may be influenced by changes in circulating nonglucose substrates (e.g., alanine, free fatty acids, and ketone bodies) as well as by hormonal factors acting on both hepatic and extrahepatic tissues.
Effects of Long-Term Optimization and Short-Term Deterioration of Glycemic Control on Glucose Counterregulation in Type I Diabetes Mellitus
Bolli, Geremia B. , Feo, Pierpaolo De , Cosmo, Salvatore De , Perriello, G. , Angeletti, G, Ventura, Maria Rosa, Santeusanio, Fausto, Brunetti, Paolo, Gerich, John E.

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 33 | Issue: 4 | Pages: 394-400

10.2337/diab.33.4.394 | PMID 6368295 Get It

To assess the effects of glycemie control on glucose counterregulation, rates of plasma glucose recovery from hypoglycemia and counterregulatory hormonal responses were studied in 18 C-peptide-negative patients with insulin-dependent diabetes mellitus (IDDM) before and after either improvement, no change, or deterioration in glycemic control. Hypoglycemia was induced by an i.v. insulin infusion (30 mU/m2 · min for 1 h) after maintenance of euglycemia overnight with i.v. insulin. In 13 patients with long duration of IDDM (9 ± 0.5 yr, mean ± SEM) and initially poor glycemic control (mean diurnal blood glucose, MBG 199 ± 8 mg/dl, ketoamine-HbA1 12.4 ± 0.2%; nondiabetic subjects 104 ± 4 mg/dl and 6.8 ± 0.09%, respectively), rates of plasma glucose recovery from hypoglycemia (0.30 ± 0.01 versus 0.60 ± 0.01 mg/dl · min in nondiabetic subjects, P < 0.001) and plasma glucagon (AUC 0.56 ± 0.09 versus 6.3 ± 0.50 ng/ml ·150 min in non-diabetic subjects, P < 0.01) and epinephrine (AUC 16.9 ± 0.2 versus 25.7 ± 0.2 ng/ml 150 min in nondiabetic subjects, P < 0.001) responses to hypoglycemia were impaired. Intensive therapy (three daily injections of insulin) instituted in 7 out of 13 IDDM patients for up to 9 mo improved MBG (124 ± 6 mg/dl, P < 0.01) and ketoamine-HbA1 (7.9 ± 0.02%, P < 0.01) but not rates of plasma glucose recovery (0.31 ± 0.01 mg/dl · min) and plasma glucagon (AUC 0.69 ± 0.07 ng/ml · 150 min) and epinephrine (AUC 14.9 ± 0.17 ng/ml ·150 min) responses. Similarly, no changes in glucose counterregulation were observed in the six IDDM patients in whom glycemic control was poorly maintained for 6–8 mo (MBG 201 ± 7 mg/dl, ketoamine-HbA112.3 ± 0.2%). In five patients with short duration of IDDM (11 ± 0.5 mo) and optimized glycemic control (MBG 131 ± 8 mg/dl, ketoamine-HbA1 7.9 ± 0.2%), rates of plasma glucose recovery, as well as counterregulatory responses of plasma glucagon and epinephrine, were normal. Neither deterioration of glycemic control for 2 wk (MBG 229 ± 12 mg/dl, ketoamine-HbA1 9.1 ± 0.2%) nor its improvement over the 2 subsequent wk (MBG 120 ± 8 mg/dl, ketoamine-HbA1 8.5 ± 0.2%) resulted in any significant change in glucose counterregulation. It is concluded that near-normalization of glycemic control for up to 9 mo is insufficient to reverse the impairment in glucose counterregulation found in long-term IDDM. Short-term deterioration in glycemic control, when not accompanied by alterations in counterregulatory hormone secretion, does not impair glucose counterregulation.
Position statement on ethics, equipoise and research on charged particle radiation therapy
Sheehan, Mark , Peach, Ken , Binik, Ariella , Wilson, Puthenparampil , Lodge, Mark , Kehoe, Sean , Brada, Michael, Clarke, Steve , Crellin, A., Dunn, Michael , Fossati, Piero , Harris, Steve , Hocken, Michael, Hope, Tony, Ives, Jonathan , Kamada, Tadashi , London, Alex John , Miller, Robert C. , Pijls-Johannesma, Madelon, Short, Susan , Skene, Loane, Tsujii, Hirohiko, Tuan, Jeffrey , Weijer, Charles , Timlin, Claire L. , Burnet, N.G. , Parker, Michael James , Savulescu, Julian , Short, Susan C

Mayo Clinic

Journal of Medical Ethics | September 18, 2013 | Volume: 40 | Issue: 8 | Pages: 572-575

10.1136/medethics-2012-101290 | PMID 24045770 Get It

The use of charged-particle radiation therapy (CPRT) is an increasingly important development in the treatment of cancer. One of the most pressing controversies about the use of this technology is whether randomised controlled trials are required before this form of treatment can be considered to be the treatment of choice for a wide range of indications. Equipoise is the key ethical concept in determining which research studies are justified. However, there is a good deal of disagreement about how this concept is best understood and applied in the specific case of CPRT. This report is a position statement on these controversies that arises out of a workshop held at Wolfson College, Oxford in August 2011. The workshop brought together international leaders in the relevant fields (radiation oncology, medical physics, radiobiology, research ethics and methodology), including proponents on both sides of the debate, in order to make significant progress on the ethical issues associated with CPRT research. This position statement provides an ethical platform for future research and should enable further work to be done in developing international coordinated programmes of research.
‘Initial Clinical Experience' articles are poorly cited and negatively affect the impact factor of the publishing journal: a review
Ahmed, Ahmed T. , Rezek, Issa, Mcdonald, Jennifer S, Kallmes, David F. , Mcdonald, Jennifer S

Mayo Clinic

JRSM Short Reports | April 12, 2013 | Volume: 4 | Issue: 3 | Pages: 1-4

10.1177/2042533313476694 | PMID 23560220 Get It

Objectives The phrase ‘Initial Clinical Experience' in a manuscript's title implies that the described technique offers promise of future clinical relevance. We assessed, using rates of subsequent citations, the actual academic relevance of such articles in comparison to articles not containing the phrase. Design We searched ISI database for articles that included the studied phrase in their titles between 1975 and 2009 and grouped the results by the related medical specialty. We excluded articles from journals with no available impact factor. For each identified article, we extracted number of included patients, citations/year, the average impact factor of the publishing journal over the last five years and the proportion of articles published in the same journal that garnered zero subsequent citations. Setting Retrospective review of a scientific database. Participants None Main outcome measures Citation rate Results Among a total of 982,127 articles published in 186 journals representing eight major publishing medical specialties, 531 (0.05%) were Initial Clinical Experience articles. Thirty percent of Initial Clinical Experience articles were never cited compared with 7% of the overall article volume ( p < 0.0001). Citations/year for Initial Clinical Experience articles were significantly lower than the median impact factor ( p < 0.0001). There was no correlation between citations and number of patients described in the Initial Clinical Experience articles ( p = 0.61). Conclusions Initial Clinical Experience articles are cited less frequently than the average, especially in Cardiovascular, Radiology and Ophthalmology journals.
Short- and Long-term Individual Variation in Cardiac Troponin in Patients with Stable Coronary Artery Disease
Nordenskjöld, Anna M. , Fröbert, Ole , Jaffe, Allan S. , Venge, Per , Ahlström, Håkan K. , Eggers, Kai M. , Jaffe, Allan S. , Lindahl, Bertil

Mayo Clinic

Clinical Chemistry | November 11, 2012 | Volume: 59 | Issue: 2 | Pages: 401-409

10.1373/clinchem.2012.191700 | PMID 23143329 Get It

BACKGROUND A rise or fall of cardiac troponin is a prerequisite for the diagnosis of acute myocardial infarction. Defining significant changes requires knowledge of both biological and analytical variation. The short-term biological variation of cardiac troponin in healthy individuals is 3%–48%. However, healthy individuals may not be representative for patients in whom cardiac troponin measurement is often of clinical importance. Therefore, we studied the individual variation of cardiac troponin in patients with symptoms of stable coronary artery disease. METHODS Twenty-four patients scheduled for elective coronary angiography were included. Blood samples were drawn once at enrollment and serially at six 4-h intervals on the day before coronary angiography. Cardiac troponin was measured with hs-cTn assays from Abbott Laboratories (premarket cTnI assay) and Roche Diagnostics (Elecsys® cTnT assay with two different lots). RESULTS The short-term individual variation in cardiac troponin I (cTnI) was 14%, the reference change value (RCV) 49%, and RCV-log-normal (rise/fall) 54%/−35%. The corresponding values for cTnT were 7%, 23%, and 26%/−21%. The long-term variation for cTnI was 24%, RCV 69%, and RCV-log-normal (rise/fall) 97%/−49%. The corresponding values for cTnT were 11%, 32%, and 37%/−27%. CONCLUSIONS The short-term individual variation of cardiac troponin in patients with symptoms of stable coronary artery disease is similar to the biological variation previously demonstrated in healthy individuals. Our results suggest that a change in cardiac troponin concentrations of &gt;50% can be used in attempting to diagnose acute myocardial injury. To detect significant long-term changes in cardiac troponin concentrations, larger changes will be required.
Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection
Lalezari, Jacob , Asmuth, David M. , Casiró, Arnaldo, Vargas, Hugo E. , Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie , McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao‐Jian, Sullivan-Bolyai, J., Mayers, Douglas L., Vargas, Hugo E , Lalezari, Jay

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 16, 2012 | Volume: 56 | Issue: 12 | Pages: 6372-6378

10.1128/aac.01521-12 | PMID 23070151 Get It

ABSTRACT IDX184 is a liver-targeted prodrug of 2′-methylguanosine (2′-MeG) monophosphate. This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1 chronic hepatitis C virus (HCV) infection. Forty-one patients with baseline HCV RNA ≥ 5 log 10 IU/ml, alanine aminotransferase (ALT) ≤ 2.5× the upper limit of normal, and compensated liver disease were dosed. Sequential cohorts of 10 patients, randomized 8:2 (active:placebo), received 25, 50, 75, and 100 mg of IDX184 once daily for 3 days, with a 14-day follow-up. There were no safety-related treatment discontinuations or serious adverse events. The adverse events and laboratory abnormalities observed for IDX184- and placebo-treated patients were similar. At the end of the 3-day treatment period, changes from baseline in HCV RNA levels (means ± standard deviations) were −0.5 ± 0.6, −0.7 ± 0.2, −0.6 ± 0.3, and −0.7 ± 0.5 log 10 for the 25-, 50-, 75-, and 100-mg doses, respectively, while viral load remained unchanged for the pooled placebo patients (−0.05 ± 0.3 log 10 ). Patients with genotype-1a and patients with genotype-1b responded similarly. Serum ALT levels decreased, especially at daily doses ≥ 75 mg. During the posttreatment period, plasma viremia and serum aminotransferase levels returned to near pretreatment levels. No resistance mutations associated with IDX184 were detected. Plasma exposure of IDX184 and its nucleoside metabolite 2′-MeG was dose related and low. Changes in plasma viral load correlated with plasma exposure of 2′-MeG. In conclusion, the results from this proof-of-concept study show that small doses of the liver-targeted prodrug IDX184 were able to deliver significant antiviral activity and support further clinical evaluation of the drug candidate.
Effects of Type 2 Diabetes and Insulin on Whole-Body, Splanchnic, and Leg Protein Metabolism
Short, Kevin R. , Irving, Brian A. , Basu, Ananda , Basu, Rita , Johnson, Christopher M. , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 3, 2012 | Volume: 97 | Issue: 12 | Pages: 4733-4741

10.1210/jc.2012-2533 | PMID 23032060 Get It

Faculty Opinions recommendation of A system for stable expression of short interfering RNAs in mammalian cells.
Vile, Richard G.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1006487.71406 Get It

Faculty Opinions recommendation of Cyclization of short DNA fragments and bending fluctuations of the double helix.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 19, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1025043.294784 Get It